The study provides compelling rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive B cell lymphoma as well as in preclinical models of other malignancies. This evidence concerns the gene PDCD1 and B-cell non-Hodgkin lymphoma.